Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Qu
Go back to Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Qu| Uni-Pixel, Inc. (NASDAQ: NXL) | Delayed: 0.35 -0.01 (2.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.36 | 52 Week High | $0.68 | |||
| Open | $0.36 | 52 Week Low | $0.62 | |||
| Day High | $0.37 | P/E | N/A | |||
| Day Low | $0.35 | EPS | $0.00 | |||
| Volume | 41,063 | |||||
